SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Verrica Pharmaceuticals Inc

VRCA is trending due to a significant volume spike and recent price surge, sparking community discussion around potential catalysts and trading strategies. Some traders are noting the stock's history of large moves on catalysts, while others express caution and await a pullback before considering entry. The community is also discussing recent insider buying and potential for future growth.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

CVKD is trending due to a recently announced Zacks Small Cap Research report with a price target of $30, sparking community interest. Discussions revolve around the company's acquisition of Frunexian and potential catalysts for the stock, while some express concern about a possible ATM offering. The company is also highlighted due to its recent collaboration with Abbott for its Phase 3 TECH-LVAD trial.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

Fueled by Fed rate-cut hopes, fintech stocks, including FICO, are gaining momentum, with potential growth driven by innovation.  The community is buzzing about FICO's recent partnership for a new credit score using cash-flow data and option alerts, while also weighing analyst ratings and price target adjustments. Broader discussions involve comparisons to competitors and impacts from mortgage rate fluctuations.

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed. AstraZeneca was founded in 1999 through the merger of Astra AB and Zeneca Group PLC. The company is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc - ADR

AstraZeneca PLC

AstraZeneca ($AZN) is trending due to a mix of factors including positive trial data for its cancer and hypertension treatments, as well as news regarding potential deals. Community discussions also involve speculation about potential acquisitions and partnerships within the pharmaceutical sector, including interest from other major players. The stock's valuation and growth prospects, particularly within its oncology and cardiometabolic pipelines, are also being discussed.

Renaissance Capital Greenwich Funds - Renaissance IPO ETF

The Renaissance IPO ETF ($IPO) is trending amid discussions about the broader IPO market, with attention focused on CoreWeave's (CRWV) downsized IPO and its potential as a bellwether for AI sentiment. Community analysis also highlights the overall performance of recent IPOs and the anticipation of upcoming listings across various sectors, including technology, healthcare, and energy. Investors are weighing opportunities against market volatility and sector-specific challenges.

Medical Properties Trust, Inc. is a self-advised real estate investment trust. It engages in the investment, acquisition, and development of net-leased healthcare facilities. Its property portfolio includes rehabilitation hospitals, long-term acute care hospitals, ambulatory surgery centers, hospitals for women and children, regional and community hospitals, medical office buildings, and other single-discipline facilities. The company was founded by Edward K. Aldag Jr., R. Steven Hamner, Emmett E. McLean, and William Gilliard McKenzie in 2003 and is headquartered in Birmingham, AL.

Medical Properties Trust Inc

MPW is trending as investors discuss a potential short squeeze, with the stock showing signs of recovery and trading near resistance levels. Community members are weighing the possibility of increased dividends, share buybacks, and positive outcomes from ongoing portfolio restructuring. Discussions also involve broader market factors like interest rate cuts and their potential impact on REITs.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

$PMV (PumpMindVirus) is trending due to its energetic and meme-focused community, with members actively discussing the coin's 'pressure' and potential. The community emphasizes its unique 'infection' narrative, suggesting a viral spread of awareness and adoption within the crypto space. $PMV is associated with meme culture on the SOL network.

iShares Ethereum Trust (The) - Undivided Beneficial Interest

iShares Ethereum Trust ETF

ETHA is trending as Ethereum nears all-time highs, sparking bullish sentiment and discussions around potential targets. Community members are actively analyzing options levels and whale activity, while also debating the merits of investing in ETHA versus holding Ethereum directly or exploring related treasury companies. Broader conversations encompass potential impacts of regulatory developments and the tokenization of real-world assets.

ExlService Holdings, Inc. is an operations management and analytics company, which engages in providing business process management. It operates through the following segments: Insurance, Healthcare, Travel, Transportation, and Logistics, Finance and Accounting, Analytic, and All Other. The Insurance segment serves property and casualty insurance, life insurance, disability insurance, annuity, and retirement services companies. The Healthcare segment offers services related to care management or population health, payment integrity, revenue optimization, and customer engagement. The Travel, Transportation, and Logistics segment includes business processes in corporate and leisure travel such as reservations, customer service, fulfillment, and finance and accounting. The Finance and Accounting segment is comprised of procure-to-pay, order-to-cash, hire-to-retire, record-to-report, regulatory reporting, financial planning and analysis, audit and assurance, treasury, and tax processes. The Analytics segment consists of driving improved business outcomes for customers by generating data-driven insights. The All-Other segment is involved in banking, financial, utilities, and consulting services. The company was founded by Vikram Talwar and Rohit Kapoor in April 1999 and is headquartered in New York, NY.

ExlService Holdings Inc

Exlservice Hldgs Inc

EXLS is trending as community members discuss option alerts showing substantial ROI and compare it to other trending tickers, noting a slight dip in price and trading volume. Some are analyzing potential catalysts, including its relationship with General Catalyst and ISO 20022 implementation, while others highlight institutional investment and positive analyst ratings. Broader discussions encompass AI applications in healthcare and the company's financial performance.

cat in a dogs world

MEW is trending as the community speculates on potential listings and its ability to outperform other meme coins like DOGE and SHIB. The cat-themed crypto is generating buzz for its capped supply and recent listing on Robinhood, with some anticipating a surge reminiscent of DOGE's past performance. Community members are actively discussing accumulation strategies, long-term potential, and possible price targets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Promising Pharmaceutical Stocks To Watch Today - November 28th

Eli Lilly and Company, Novo Nordisk A/S, Pfizer, AbbVie, and AstraZeneca are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are...

JNJ's Oncology Momentum Builds as It Chases $50B Goal by 2030 

JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.

Here's Why Astrazeneca (AZN) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

AstraZeneca PLC $AZN Shares Sold by Elevation Point Wealth Partners LLC

Elevation Point Wealth Partners LLC decreased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 18.7% in the 2nd quarter, according to the company in its most recent disclosure...

AstraZeneca or Merck: Which Oncology Giant Has the Edge? 

AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.

Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

AstraZeneca PLC $AZN Shares Acquired by Thornburg Investment Management Inc.

Thornburg Investment Management Inc. increased its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 3.6% in the second quarter, according to its most recent 13F filing with the Securities...

<ul class="summary-bullets"><li>Analysts said Medicare’s drug-price cuts were smaller or already reflected in forecasts.</li><li>Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.</li><li>Retail traders on Stocktwits turned extremely bullish on LABU as message volume surged.</li></ul><p>The biotech sector rallied sharply on Wednesday after Wall Street analysts said the latest round of U.S. Medicare drug-price cuts would have a smaller impact on pharmaceutical companies than initially feared, lifting the Direxion Daily S&amp;P Biotech Bull 3X Shares ETF (LABU) to its highest level in nearly 20 months.</p><p>The&nbsp;<a href="https://stocktwits.com/symbol/LABU">LABU ETF</a> extended its rally on Wednesday, rising 3.7% to close at $165.5 and edging up 0.2% after hours, marking its fourth straight session of gains.</p><h2 class="st-heading-2"><strong>Bernstein Says Semaglutide Pricing Is ‘Final Cloud To Clear’</strong></h2><p>Shares of major drugmakers jumped after the U.S. government published negotiated Medicare prices for 15 drugs late Tuesday, with cuts of up to 85% scheduled to begin in 2027.</p><p>Novo Nordisk’s U.S.-listed shares rose&nbsp;nearly 4%, and Teva Pharmaceuticals gained over 5%, after their flagship therapies appeared on the pricing list. Novo’s semaglutide drugs, Ozempic and Wegovy, along with Teva’s Austedo, were included among the treatments subject to reductions.</p><p>Bernstein analyst Christian Moore said the negotiated price for Novo’s semaglutide was “the final cloud to clear on the drawn-out, but positively resolved GLP-1 pricing debate,” Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-shares-rise-us-medicare-price-cuts-come-largely-expected-2025-11-26/">reported</a>.</p><h2 class="st-heading-2"><strong>Goldman Sachs Says Austedo Cut Milder Than Expected</strong></h2><p>Goldman Sachs analyst Matt Dellatorre noted that Austedo’s 38% price cut came in lower than the roughly 45% reduction modeled. He said the updated government price, which is a little over $700 lower per monthly supply versus one estimate of its net price, was below expectations and therefore less damaging for Teva.</p><h2 class="st-heading-2"><strong>Guggenheim Flags Deeper Than Expected Cuts For AbbVie</strong></h2><p>Guggenheim analyst Vamil Divan said AbbVie’s cuts on Linzess and Vraylar, which come up to 75% and 44%, respectively, were deeper than anticipated.</p><p>Two analysts said they are now watching how Medicare plans will manage access to the first batch of 10 drugs whose new negotiated prices take effect in January 2026, and what the Feb. 1 announcement of the next 15 drugs for 2028 will reveal.</p><h2 class="st-heading-2"><strong>Bernstein, William Blair, And Others Say Impact Already Priced In</strong></h2><p>Bernstein analysts said five of the 15 targeted medicines will be generic by 2027, limiting exposure to deeper cuts. They added that lower prices could keep patients on branded therapies longer, potentially supporting volumes.</p><p>William Blair analysts said the $274 monthly Medicare price for Novo’s semaglutide broadly tracks recent government agreements but added that insurance-coverage expansion remains uncertain. Analysts also said reductions had already been reflected in forecasts for Novo Nordisk, AstraZeneca and GSK.&nbsp;</p><p>Earlier this month, Novo said it expected a low single-digit global sales impact if pricing were implemented this year, which analysts indicated translates to roughly DKK 6 billion.</p><h2 class="st-heading-2"><strong>Liquidity Wave Drives LABU Frenzy On Stocktwits</strong></h2><p>On Stocktwits, retail sentiment for LABU was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img style="aspect-ratio:970/143;" src="https://news.stocktwits-cdn.com/labu_ss_png_d696fb5c91.webp" alt="labu ss.png" width="970" height="143"><figcaption>LABU sentiment and message volume as of November 26 | Source: Stocktwits</figcaption></figure><p>One user said, “This concentrated burst of purchasing power is pushing up prices.”</p><p><stembedurl>https://stocktwits.com/JesusHolbrook/message/637590765</stembedurl></p><p>Another user said the move looks close to a blow-off top, possibly around $165–$175, and warned that any pullback could echo the sharp drop seen after the Covid peak.</p><p><stembedurl>https://stocktwits.com/bottomfishtrader/message/637525624</stembedurl></p><p>The LABU ETF has risen 22% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The LABU ETF has risen 22% so far in 2025. (Photo credit: Getty Images)

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

Equity

Promising Pharmaceutical Stocks To Watch Now - November 26th

Eli Lilly and Company, Novo Nordisk A/S, AbbVie, Pfizer, Teva Pharmaceutical Industries, AstraZeneca, and Gilead Sciences are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...

Rep. Lisa C. McClain Purchases Shares of AstraZeneca PLC (NASDAQ:AZN)

Representative Lisa C. McClain (R-Michigan) recently bought shares of AstraZeneca PLC (NASDAQ:AZN). In a filing disclosed on November 21st, the Representative disclosed that they had bought between...

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$1.07	--	--	N/A
Q3 '25	$1.15	$1.19	3.81%	BEAT
Q2 '25	$1.07	$1.09	1.02%	BEAT
Q1 '25	$1.12	$1.25	11.65%	BEAT
Q4 '24	$1.04	$1.04	0.03%	BEAT

AZN
AstraZeneca PLC

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest AZN News

AZNAstraZeneca PLC